You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,638,949


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,638,949
Title: Prevention of adhesions and excessive scar formation using angiogenesis inhibitors
Abstract:A method and compositions for inhibiting excessive scar formation and adhesions by administering to a patient in need thereof an effective amount of an angiogenesis inhibitor. In the preferred embodiment, the angiogenesis inhibitor is selective, such as a fumagillol derivative like 0-chloroacetylcarbamoyl-Fumagillol (TNP-470, TAP Pharmaceuticals), thalidomide, or a selective drug having more than one activity, such as minocycline or penicilliamine which also have antibiotic activity. Less selective compounds can also be used, such as the cytokine IL12. Patients to be treated include those having experienced trauma, surgical intervention, burns, and other types of injuries. The inhibitor is administered in an amount effective to decrease excessive scarring, defined as formation of high density tissue including cells and connective tissue, without preventing normal wound closure. The inhibitors can be administered systemically and/or locally or topically, as needed. For prevention of adhesions, the angiogenesis inhibitor would typically be applied at the time of surgery, preferably in a controlled release formulation and/or using barrier technology.
Inventor(s): Folkman; Judah (Brookline, MA), Brem; Harold (New York, NY), Ehrlich; H. Paul (Grantville, PA)
Assignee:
Application Number:09/139,375
Patent Claims:1. A method to inhibit excessive scar formation and adhesions comprising administering to a patient in need thereof an effective amount of an angiogenesis inhibitor selected from the group consisting of collagenase inhibitors, penicillamine, and IL12.

2. The method of claim 1 wherein the angiogenesis inhibitor is administered systemically.

3. The method of claim 1 wherein the angiogenesis inhibitor is administered topically or locally at the site of a wound.

4. The method of claim 1 wherein the angiogenesis inhibitor is administered to prevent or inhibit formation of hypertrophic scarring.

5. The method of claim 1 wherein the angiogenesis inhibitor is administered to prevent or inhibit formation of keloid scarring.

6. A method for inhibiting surgical adhesions or burn contractions comprising administering to the site an effective amount of angiogenesis inhibitor selected from the group comprising thalidomide, collagenase inhibitors, penicillamine, and IL12.

7. The method of claim 1 wherein the angiogenesis inhibitor is an antibiotic.

8. The method of claim 6 wherein the angiogenesis inhibitor is thalidomide.

9. A method for inhibiting surgical adhesions or burn contractions comprising administering to the site an effective amount of fumigillin in a pharmaceutically acceptable topical carrier selected from the group consisting of an ointment, gel spray, and paste, for application to a wound.

10. A composition for application to a wound comprising a polymeric barrier or implant comprising an angiogenesis inhibitor selected from the group comprising thalidomide, fumigillin, collagenase inhibitors, and penicillamine, in a dosage formulation comprising a pharmaceutically acceptable carrier for topical application in an amount effective to prevent or inhibit formation of hypertrophic scars or keloid scars, adhesions or burn contractions.

11. A composition comprising an angiogenesis inhibitor selected from the group consisting of collagenase inhibitors and penicillamine, in a pharmaceutically acceptable carrier for topical application of the inhibitor selected from the group consisting of an ointment, gel, spray, and paste.

12. The composition of claim 10 wherein the angiogenesis inhibitor is thalidomide.

13. The composition of claim 10 wherein the angiogenesis inhibitor is in a controlled release formulation which releases an effective amount of angiogenesis inhibitor to prevent or inhibit hypertrophic scar or keloid scar formation over the time period required for healing of a wound.

14. The composition of claim 10 wherein the angiogenesis inhibitor is in a formulation delivering sustained release of an effective amount of angiogenesis inhibitor to prevent or inhibit hypertrophic scar or keloid scar formation over the time period required for healing of a wound.

15. The composition of claim 10 in a dosage not inhibiting normal wound healing.

16. The method of claim 1 wherein the angiogenesis inhibitor is a collagenase inhibitor.

17. The method of claim 1 wherein the angiogenesis inhibitor is penicillamine.

18. The method of claim 1 wherein the angiogenesis inhibitor is IL12.

19. The method of claim 6 wherein the angiogenesis inhibitor is a collagenase inhibitor.

20. The method of claim 6 wherein the angiogenesis inhibitor is penicillamine.

21. The method of claim 6 wherein the angiogenesis inhibitor is IL12.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.